CT103A

未知生产厂商

CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。